ArticleMedicine2026
Development and validation of a prognostic nomogram for overall survival in patients with primary cutaneous T-cell lymphoma: A SEER-based study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of cutaneous T-cell lymphoma (CTCL) remains heterogeneous, and clinically applicable prognostic tools are needed. Using population-based Surveillance, Epidemiology, and End Results (SEER) data (2000-2019), we analyzed incidence trends and developed a prognostic nomogram for overall survival. Incidence rates were assessed by joinpoint regression. Patients diagnosed from 2004 to 2010 formed the training cohort (n = 4316), and those from 2011 to 2015 constituted the temporal validation cohort (n = 2875). Multivariable Cox analysis identified independent prognostic factors, which were incorporated into a nomogram predicting 1-, 3- and 5-year overall survival. Among 7191 patients, CTCL incidence increased from 2000 to 2016 [annual percent change (APC) 1.05%] and then declined through 2019 (APC -8.44%). The nomogram integrates 11 variables: age, sex, race, marital status, histological subtype, median household income, TNM stage, prior malignances, surgery, radiation, and chemotherapy. It demonstrated strong discrimination, with time-dependent area under the curve values >0.815 for all timepoints in both cohorts, and good calibration. Based on nomogram-derived scores, patients were stratified into 3 distinct risk groups with significantly different survival (P < .0001). This SEER-based nomogram provides a practical, multivariable tool for risk stratification in CTCL, using routinely available clinical and demographic data. External validation is warranted to confirm its generalisability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.